Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 7/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
| ▸ | MIF | P14174 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29955278 | 0.86 | ATR (0.44) | SCN9ALCKGSK3BDYRK1ACA1 | |
| SCHEMBL6183699 | 0.83 | CYP1A2 (0.41) | SCN9ALCKGSK3BDYRK1ACA1 | |
| SCHEMBL30711674 | 0.82 | LCK (0.51) | LCK | |
| SCHEMBL2113744 | 0.82 | LCK (0.51) | LCK | |
| SCHEMBL23467642 | 0.79 | LCK (0.48) | SCN9ALCKGSK3BDYRK1ACA1 | |
| SCHEMBL21590399 | 0.79 | CYP1A2 (0.41) | SCN9ALCKGSK3BDYRK1AATR | |
| SCHEMBL22809486 | 0.79 | PIK3CG (0.45) | LCK | |
| SCHEMBL22213871 | 0.77 | AAK1 (0.38) | SCN9ALCKGSK3BDYRK1ACA1 | |
| SCHEMBL1838240 | 0.77 | LCK (0.46) | SCN9ALCKGSK3BDYRK1ACA1 | |
| SCHEMBL1258539 | 0.77 | ATR (0.47) | GSK3BDYRK1ACA1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136790-A1 | Tricyclic Heterocyclic Derivatives and Methods of Use | DE LERA RUIZ MANUEL | 2011-06-09 | — | — | US | disclosed |
| US-20110136790-A1 | Tricyclic Heterocyclic Derivatives and Methods of Use | DE LERA RUIZ MANUEL | 2011-06-09 | — | — | US | disclosed |
| US-7638531-B2 | Phenoxypiperidines and analogs thereof useful as histamine H3 antagonists | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-7531660-B2 | 1-[[1-[(2-amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-B]pyridin-3-YL]piperidine and methods of use thereof | SCHERING CORPORATION (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531660-B2 | 1-[[1-[(2-amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-B]pyridin-3-YL]piperidine and methods of use thereof | SCHERING CORPORATION (US) | 2009-05-12 | — | — | US | disclosed |
| EP-1931665-A1 | 1-[[1-[(2-AMIN0-6-METHYL-4-PYRIDINYL)METHYL]-4-FLU0R0-4-PIPERIDINYL,]CARBONYL]-4-[2-(2-PYRIDINYL)-3H-IMIDAZ0[4, 5-B]PYRIDIN-3-YL]PIPERIDINE USEFUL AS HISTAMINE H3 ANTAGONIST | SCHERING CORPORATION (US) | 2008-06-18 | — | — | EP | disclosed |
| US-20080058370-A1 | 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine and Methods of Use Thereof | SCHERING CORPORATION | 2008-03-06 | — | — | US | disclosed |
| US-20080058370-A1 | 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine and Methods of Use Thereof | SCHERING CORPORATION | 2008-03-06 | — | — | US | disclosed |
| US-7332604-B2 | 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine | SCHERING CORPORATION (US) | 2008-02-19 | — | — | US | disclosed |
| US-7332604-B2 | 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine | SCHERING CORPORATION (US) | 2008-02-19 | — | — | US | disclosed |
| WO-2007075629-A2 | PHENOXYPIPERIDINES AND ANALOGS THEREOF USEFUL AS HISTAMINE H3 ANTAGONISTS | SCHERING CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| WO-2007035703-A1 | 1- [ [1- [ (2-AMIN0-6-METHYL-4-PYRIDINYL) METHYL] -4-FLU0R0-4-PIPERIDINYL,] CARBONYL] -4- [2- (2-PYRIDINYL) -3H-IMIDAZ0 [4 , 5-B] PYRIDIN-3-YL] PIPERIDINE USEFUL AS HISTAMINE H3 ANTAGONIST | SCHERING CORPORATION (US) | 2007-03-29 | — | — | WO | disclosed |
| WO-2007035703-A1 | 1- [ [1- [ (2-AMIN0-6-METHYL-4-PYRIDINYL) METHYL] -4-FLU0R0-4-PIPERIDINYL,] CARBONYL] -4- [2- (2-PYRIDINYL) -3H-IMIDAZ0 [4 , 5-B] PYRIDIN-3-YL] PIPERIDINE USEFUL AS HISTAMINE H3 ANTAGONIST | SCHERING CORPORATION (US) | 2007-03-29 | — | — | WO | disclosed |
| US-20070066644-A1 | 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine | SCHERING CORPORATION | 2007-03-22 | — | — | US | disclosed |
| US-20070066644-A1 | 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine | SCHERING CORPORATION | 2007-03-22 | — | — | US | disclosed |
| EP-1404672-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2006-01-18 | — | — | EP | disclosed |
| US-6875767-B2 | (5-cyano-2-thiazolyl)amino-4-pyridine tyrosine kinase inhibitors | MERCK & CO., INC. (US) | 2005-04-05 | — | — | US | disclosed |
| EP-1404672-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030100567-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2003-05-29 | — | — | US | disclosed |
| WO-2003000687-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066644-A1 | 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine | FABP1, GPR119, FABP4 | SCN9A 3571/4885LCK 2845/4885GSK3B 1877/4885 |
| US-20110136790-A1 | Tricyclic Heterocyclic Derivatives and Methods of Use | GPR119, CNR1, CNR2 | SCN9A 1631/4885LCK 2924/4885GSK3B 4303/4885 |
| US-20080058370-A1 | 1-[[1-[(2-Amino-6-methyl-4-pyridinyl)methyl]-4-fluoro-4-piperidinyl]carbonyl]-4-[2-(2-pyridinyl)-3H-imidazo[4,5-b]pyridin-3-yl]piperidine and Methods of Use Thereof | FABP1, LIPC, GPR119 | SCN9A 3916/4885LCK 2811/4885GSK3B 1953/4885 |
| US-20030100567-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | SCN9A 4740/4885LCK 16/4885GSK3B 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.